Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

40.69USD
19 Apr 2018
Change (% chg)

$-0.05 (-0.12%)
Prev Close
$40.74
Open
$40.82
Day's High
$41.20
Day's Low
$40.54
Volume
139,928
Avg. Vol
1,792,945
52-wk High
$47.81
52-wk Low
$29.44

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.33
Market Cap(Mil.): $20,972.21
Shares Outstanding(Mil.): 514.78
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 26.50 30.61 33.50
EPS (TTM): 1.54 -- --
ROI: 2.79 13.57 13.17
ROE: 6.75 15.25 14.98

EpiPen shortages seen in Canada, UK but U.S. supply intact

NEW YORK Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.

Apr 14 2018

EpiPen shortages seen in Canada, UK but U.S. supply intact

NEW YORK, April 13 Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.

Apr 13 2018

Deals of the day-Mergers and acquisitions

April 13 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

Apr 13 2018

Mylan seeks deal for German Merck's consumer products unit: sources

FRANKFURT/NEW YORK Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.

Apr 13 2018

UPDATE 2-Mylan seeks deal for German Merck's consumer products unit -sources

FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.

Apr 13 2018

Mylan seeks deal for German Merck’s consumer products unit -sources

FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.

Apr 13 2018

BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam

* MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC

Apr 11 2018

BRIEF-Mylan NV Says Reaffirming 2018 Guidance

* FY2018 EARNINGS PER SHARE VIEW $5.38, REVENUE VIEW $12.44 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Apr 11 2018

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

Apr 11 2018

BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics

* MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)

Apr 11 2018

Earnings vs. Estimates